Life Sciences

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005
13 October 2021

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage cocktails that target...

Read the press release
Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders
13 October 2021

Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological diseases, today announced the completion of a $37.25...

Read more
Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA
5 October 2021

Vedanta Announces Positive Topline Phase 2 Data for VE303 in High- Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that its Phase...

Read the press release
A-Mansia Biotech’s pasteurised Akkermansia muciniphila is the firt next generation bacterium to get green light from EFSA’s cientific council
2 September 2021

A-Mansia Biotech’s pasteurised Akkermansia muciniphila is the firt next generation bacterium to get green light from EFSA’s cientific council

A crucial step has been taken by Belgian company A-Mansia Biotech, a co-spin-off of Wageningen University and UCLouvain. The European Food Safety Authority (EFSA) considers the...

Read the press release
Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics
16 June 2021

Enterome’s GeneMark-HM software highlighted as the most accurate microbiome gene prediction software in peer-reviewed publication NAR Genomics and Bioinformatics

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code the molecular interactions in the gut microbiome impacting...

Read the press release
Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression
15 June 2021

Eligo presents preclinical data demonstrating for the first time that Gut Microbiome Modulation via delivery of CRISPR nuclease impacts disease progression

Eligo Bioscience SA, a Paris, France-based microbiome engineering company, today announced that the Company presented preclinical data on its lead drug candidate, EB003, for...

Read the press release
Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors
24 March 2021

Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors

Phase1/2 clinical trials in patients with follicular lymphoma and marginal zone lymphoma expected to begin in Q2 2021

ENTEROME SA, a clinical stage biopharmaceutical...

Read the press release
MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease
17 March 2021

MaaT Pharma Announces Positive Topline Results from Phase 2 HERACLES Clinical Trial with Lead Microbiome Ecosystem Therapy MaaT013 in Patients with Acute Graft-versus-Host Disease

MaaT Pharma announced today positive topline results from its Phase 2 clinical trial evaluating lead microbiome ecosystem therapy, MaaT013, in a high-risk patient population...

Read the press release